IL317722A - Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide - Google Patents
Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamideInfo
- Publication number
- IL317722A IL317722A IL317722A IL31772224A IL317722A IL 317722 A IL317722 A IL 317722A IL 317722 A IL317722 A IL 317722A IL 31772224 A IL31772224 A IL 31772224A IL 317722 A IL317722 A IL 317722A
- Authority
- IL
- Israel
- Prior art keywords
- cyanothiazolidin
- morpholinoquinoline
- oxoethyl
- carboxamide
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263366696P | 2022-06-21 | 2022-06-21 | |
| PCT/EP2023/066559 WO2023247487A1 (en) | 2022-06-21 | 2023-06-20 | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317722A true IL317722A (en) | 2025-02-01 |
Family
ID=87047690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317722A IL317722A (en) | 2022-06-21 | 2023-06-20 | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250368637A1 (en) |
| EP (1) | EP4543877A1 (en) |
| JP (1) | JP2025521304A (en) |
| KR (1) | KR20250027736A (en) |
| CN (2) | CN120554349A (en) |
| AU (1) | AU2023288645A1 (en) |
| CA (1) | CA3260370A1 (en) |
| CL (1) | CL2024003894A1 (en) |
| IL (1) | IL317722A (en) |
| MA (1) | MA71234A (en) |
| MX (1) | MX2024015644A (en) |
| WO (1) | WO2023247487A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026119802A1 (en) | 2024-12-02 | 2026-06-11 | Astrazeneca Ab | Dosing regimen for the treatment of fap-mediated conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| CN113811529A (en) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | fibroblast-activated protein inhibitor |
| UY39569A (en) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-CYANOTHIAZOLIDIN-3-IL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES |
-
2023
- 2023-06-20 AU AU2023288645A patent/AU2023288645A1/en active Pending
- 2023-06-20 CN CN202510664265.XA patent/CN120554349A/en active Pending
- 2023-06-20 WO PCT/EP2023/066559 patent/WO2023247487A1/en not_active Ceased
- 2023-06-20 US US18/871,230 patent/US20250368637A1/en active Pending
- 2023-06-20 IL IL317722A patent/IL317722A/en unknown
- 2023-06-20 JP JP2024573909A patent/JP2025521304A/en active Pending
- 2023-06-20 EP EP23734210.0A patent/EP4543877A1/en active Pending
- 2023-06-20 MA MA71234A patent/MA71234A/en unknown
- 2023-06-20 CN CN202380047913.6A patent/CN119585266A/en active Pending
- 2023-06-20 KR KR1020257002002A patent/KR20250027736A/en active Pending
- 2023-06-20 CA CA3260370A patent/CA3260370A1/en active Pending
-
2024
- 2024-12-16 MX MX2024015644A patent/MX2024015644A/en unknown
- 2024-12-17 CL CL2024003894A patent/CL2024003894A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023247487A1 (en) | 2023-12-28 |
| US20250368637A1 (en) | 2025-12-04 |
| EP4543877A1 (en) | 2025-04-30 |
| JP2025521304A (en) | 2025-07-08 |
| KR20250027736A (en) | 2025-02-27 |
| MA71234A (en) | 2025-04-30 |
| CN120554349A (en) | 2025-08-29 |
| MX2024015644A (en) | 2025-02-10 |
| CN119585266A (en) | 2025-03-07 |
| AU2023288645A1 (en) | 2025-02-13 |
| CA3260370A1 (en) | 2023-12-28 |
| CL2024003894A1 (en) | 2025-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54526A (en) | NEW POLYMORPHIC FORMS OF A TGFBeta INHIBITOR | |
| EP3947361A4 (en) | SALT AND CRYSTALLINE FORM OF A FAK INHIBITOR | |
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
| IL279173A (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| EP3990448A4 (en) | Heterocyclic compounds as inhibitors of kras g12c | |
| AU2021403827A1 (en) | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides | |
| EP3856164A4 (en) | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS | |
| DK4055021T3 (en) | HETEROCYCLIC RIP1 INHIBITOR COMPOUNDS | |
| IL289594A (en) | New heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| EP3870181A4 (en) | CRYSTALLINE FORMS OF AN ALK2 INHIBITOR | |
| PE20170705A1 (en) | NEW COMPOUNDS AS RET INHIBITORS (REORGANIZED DURING TRANSFECTION) | |
| IL289140A (en) | Monitoring surface cleaning of medical surfaces using video streaming | |
| IL288936A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| MX2021010133A (en) | CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOQUINOLIN-5-IL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-IL)-1H-PYRAZOLE-4-CARBOX MONOHYDRATED AMIDE. | |
| IL290289A (en) | Amide hybridization of amphotericin b | |
| DK3986401T3 (en) | The peptidomimetic (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide for use in the treatment of amyotrophic lateral sclerosis | |
| IL285763A (en) | Solid polymorphs of the flana-binding compound and its hydrochloride salts | |
| EP3996707A4 (en) | CRYSTALLINE FORMS OF PLASMA KALLICREIN INHIBITORS | |
| EP4241375A4 (en) | SOLID-STATE TRANSFORMER CONTROL | |
| HK40125946A (en) | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide | |
| AR104935A1 (en) | CRYSTAL FORMS OF A HISTONA DEACETILASA INHIBITOR | |
| EP4069229A4 (en) | SOLID STATE FORMS OF HDAC INHIBITOR | |
| EP4743400A1 (en) | CATHOD OF GROUP 14 - GROUP 1 | |
| EP3851438A4 (en) | BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC AND APPLICATION OF THE SAME |